The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment

Abstract:  Breast cancer that lacks expression of estrogen/progesterone receptors and overexpression of the human epidermal growth factor receptor2 (HER2), i.e. triple‐negative breast cancer (TNBC), is not amenable to current targeted therapies and carries a poor prognosis. This review discusses the natural history of TNBC and published literature in the relevant treatment landscape, with a focus on newer therapies. Compared with other subtypes of breast cancer, TN tumors have higher response rates to neoadjuvant chemotherapy; however, this advantage is not clearly translated into the metastatic setting and has not improved these patients’ overall survival. Numerous cytotoxic and targeted strategies have demonstrated efficacy or are under investigation. Strategies showing promise in this difficult‐to‐treat group of patients include cytotoxic therapy with platinum‐containing agents, ixabepilone, and novel targeted approaches such as poly(ADP‐ribose) polymerase inhibitors.

[1]  Huang Jun,et al.  Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype , 2014 .

[2]  C. Hudis,et al.  A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[4]  J. Wanders,et al.  A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Greil,et al.  Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Kern,et al.  Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Hyunna Lee,et al.  The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer. , 2010 .

[8]  R. Kimmig,et al.  Primary systemic chemotherapy with carboplatin AUC 6 and docetaxel 75 mg/m2 (q3w) in triple-negative early breast cancer. , 2010 .

[9]  R. Gray,et al.  A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). , 2010 .

[10]  J. Wanders,et al.  Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. , 2010, Clinical breast cancer.

[11]  J. Lubiński,et al.  Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Schally,et al.  Effective treatment of triple-negative breast cancer with targeted cytotoxic somatostatin analogue AN-162 (AEZS-124). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Gradishar,et al.  Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Amadori,et al.  Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[16]  Jung-Hyun Yang,et al.  Heterogeneity of Triple Negative Breast Cancer (TNBC): TNBC Might Be Divided into Two or More Subgroups by Clinicopathologic Findings. , 2009 .

[17]  D. Dizon,et al.  Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Rinaldo,et al.  Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. Tutt,et al.  Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Tsuda,et al.  Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Clynes,et al.  Activity of dasatinib with chemotherapy in triple-negative breast cancer cells. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Pegram,et al.  Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Z. Mulla,et al.  Incidence of triple negative breast cancer phenotype in a predominantly Hispanic cohort. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Chua,et al.  Triple-negative breast cancer in Hong Kong Chinese patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Ordentlich,et al.  Ex-vivo analysis of the isoform selective histone deacetylase inhibitor entinostat in triple-negative breast cancer tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Jelić,et al.  Late relapse in triple negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Maiti,et al.  The association of metabolic syndrome with triple-negative breast cancer , 2010, Breast Cancer Research and Treatment.

[28]  A. Melnick,et al.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models , 2009, Proceedings of the National Academy of Sciences.

[29]  G. Mufti,et al.  Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes , 2009, Haematologica.

[30]  M. Clynes,et al.  Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  F. Esteva,et al.  Survival among women with triple receptor-negative breast cancer and brain metastases. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[34]  L. Brinton,et al.  Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years , 2009, Cancer Epidemiology Biomarkers & Prevention.

[35]  J. Ahn,et al.  Treatment outcomes and clinicopathologic characteristics of triple‐negative breast cancer patients who received platinum‐containing chemotherapy , 2009, International journal of cancer.

[36]  Jeff Myers,et al.  Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. , 2009, Clinical breast cancer.

[37]  J. Baselga,et al.  Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Perez,et al.  Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. , 2009 .

[39]  N. Ibrahim,et al.  Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. , 2009 .

[40]  G. Hortobagyi,et al.  Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Tadashi Kobayashi,et al.  EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. , 2009, Oncology reports.

[42]  T. Lash,et al.  Triple-negative breast cancers are increased in black women regardless of age or body mass index , 2009, Breast Cancer Research.

[43]  S. Narod,et al.  Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers , 2009, Breast Cancer Research and Treatment.

[44]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[45]  A. Davies,et al.  Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. , 2008, The oncologist.

[46]  L. Carey,et al.  What is triple-negative breast cancer? , 2008, European journal of cancer.

[47]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[48]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[49]  Wen-hong Zhou,et al.  Clinicopathologic and Prognostic Characteristics of Triple-Negative Breast Cancer , 2008, Oncology Research and Treatment.

[50]  Katsunobu Sakurai,et al.  Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers , 2008, International Journal of Clinical Oncology.

[51]  M. Piontek,et al.  Clinical activity of ixabepilone, a novel epothilone b analog, across the breast cancer disease continuum , 2008 .

[52]  H. Kaplan,et al.  Impact of Triple Negative Phenotype on Breast Cancer Prognosis , 2008, The breast journal.

[53]  O. Brawley,et al.  High prevalence of triple‐negative tumors in an urban cancer center , 2008, Cancer.

[54]  E. Yıldırım,et al.  The prognostic importance of triple negative breast carcinoma. , 2008, Breast.

[55]  R. Mehta.  Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Daniel Birnbaum,et al.  How basal are triple‐negative breast cancers? , 2008, International journal of cancer.

[57]  C. Perou,et al.  TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer , 2008 .

[58]  S. Johnston,et al.  Platinum-based chemotherapy in triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  S. Duffy,et al.  Reply: Early onset breast cancer in black British women: a letter to the editor of British Journal of Cancer regarding early onset of breast cancer in a group of British black women , 2008, British Journal of Cancer.

[60]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Nishimura,et al.  Is triple negative a prognostic factor in breast cancer? , 2008, Breast cancer.

[62]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J. Blay,et al.  Trabectedin and its potential in the treatment of soft tissue sarcoma , 2008, Therapeutics and clinical risk management.

[64]  Guangyu Liu,et al.  Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. , 2008, Oncology reports.

[65]  C. Perou,et al.  Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.

[66]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[67]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[68]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[69]  S. Michiels,et al.  Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[71]  J. Dering,et al.  Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.

[72]  Donald Berry,et al.  Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 , 2006, Breast Cancer Research.

[73]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[74]  K. Bland,et al.  Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[76]  Donald A. Berry,et al.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .

[77]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[78]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[79]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[80]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[81]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Jasin,et al.  Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. , 2001, Cancer research.

[83]  R. Weichselbaum,et al.  The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.

[84]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.